Vaccines – Page 3

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

2 months ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

All innuendo and conspiracy: RFK Jr.’s vaccine advisory overhaul undermines vaccine confidence, experts say

2 months ago talkbio0Tagged ACIP, advisory, conspiracy, overhaul, public health medicine (field), RFK Jr., Self Confidence, Vaccines

RFK Jr.; vaccine advisory; ACIP; public health; conspiracy; confidence; overhaul

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

3 months ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

3 months ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations

3 months ago talkbio0Tagged age restriction, Approved, conditions, COVID19 (disease), Effectiveness, mNEXSPIKE, Moderna, mRNA-1283, next-generation vaccine, respiratory virus season, United States Food and Drug Administration, Vaccines

Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy